The impact of glucose disorders on cognition and brain volumes in the elderly: the Sydney Memory and Ageing Study
详细信息 查看全文
- 作者：Katherine Samaras (1) (2)
Helen L. Lutgers (1)
Nicole A. Kochan (3) (7)
John D. Crawford (3)
Lesley V. Campbell (1) (2)
Wei Wen (3) (7)
Melissa J. Slavin (3) (5)
Bernard T. Baune (4)
Darren M. Lipnicki (3)
Henry Brodaty (3) (5)
Julian N. Trollor (3) (6)
Perminder S. Sachdev (3) (7) - 关键词：Diabetes ; Glucose ; Cognition ; Dementia ; Brain ; Inflammation
- 刊名：AGE
- 出版年：2014
- 出版时间：April 2014
- 年：2014
- 卷：36
- 期：2
- 页码：977-993
- 全文大小：3,125 KB
- 参考文献：1. Alberti KG, Zimmet P, Shaw J (2005) The metabolic syndrome—a new worldwide definition. Lancet 366:1059-062 CrossRef
2. Anderson TM, Sachdev PS, Brodaty H, Trollor JN, Andrews G (2007) Effects of sociodemographic and health variables on Mini-Mental State Exam scores in older Australians. Am J Geriatr Psychiatry 15:467-76 CrossRef
3. Arlt S, Schwedhelm E, Kolsch H, Jahn H, Linnebank M, Smulders Y, Jessen F, Boger RH, Popp J (2012) Dimethylarginines, homocysteine metabolism, and cerebrospinal fluid markers for Alzheimer’s disease. J Alzheimer's dis : JAD 31:751-58
4. Ashburner J (2007) A fast diffeomorphic image registration algorithm. Neuroimage 38:95-13 CrossRef
5. Ashburner J, Friston KJ (2000) Voxel-based morphometry—the methods. Neuroimage 11:805-21 CrossRef
6. Association AD (2012) Diagnosis and classification of diabetes mellitus. Diabetes Care 35(Suppl 1):S64–S71 CrossRef
7. Baune BT, Smith E, Reppermund S, Air T, Samaras K, Lux O, Brodaty H, Sachdev PS, Trollor JN (2012) Inflammatory biomarkers predict depressive, but not anxiety symptoms during aging: the prospective Sydney Memory and Aging Study. Psychoneuroendocrinology 37:1521-530 CrossRef
8. Benton AL (1967) Problems of test construction in the field of aphasia. Cortex 3:32-8 CrossRef
9. Benton Sivan A, Spreen O (1996) Der Benton test. 7th edn. Huber, Bern.
10. Bermejo P, Martin-Aragon S, Benedi J, Susin C, Felici E, Gil P, Ribera JM, Villar AM (2008) Peripheral levels of glutathione and protein oxidation as markers in the development of Alzheimer’s disease from mild cognitive impairment. Free Radic Res 42:162-70 CrossRef
11. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P (2006) Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 5:64-4 CrossRef
12. Bosco D, Costa R, Plastino M, Branca D, Cotronei P, Sperli T, Santacroce N, Siniscalchi A, Consoli D, Ceccotti C, Mungari P, Fava A (2009) Glucose metabolism in the idiopathic blepharoptosis: utility of the Oral Glucose Tolerance Test (OGTT) and of the Insulin Resistance Index. J Neurol Sci 284:24-8 CrossRef
13. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 261:921-23 CrossRef
14. Cowie CC, Rust KF, Ford ES, Eberhardt MS, Byrd-Holt DD, Li C, Williams DE, Gregg EW, Bainbridge KE, Saydah SH, Geiss LS (2009) Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-994 and 2005-006. Diabetes Care 32:287-94 CrossRef
15. Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, Arbuckle M, Callaghan M, Tsai E, Plymate SR, Green PS, Leverenz J, Cross D, Gerton B (2012) Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 69:29-8 CrossRef
16. de Bresser J, Tiehuis AM, van den Berg E, Reijmer YD, Jongen C, Kappelle LJ, Mali WP, Viergever MA, Biessels GJ (2010) Progression of cerebral atrophy and white matter hyperintensities in patients with type 2 diabetes. Diabetes Care 33:1309-314 CrossRef
17. Elias PK, Elias MF, D’Agostino RB, Cupples LA, Wilson PW, Silbershatz H, Wolf PA (1997) NIDDM and blood pressure as risk factors for poor cognitive performance. The Framingham Study. Diabetes Care 20:1388-395 CrossRef
18. Engelhart MJ, Geerlings MI, Meijer J, Kiliaan A, Ruitenberg A, van Swieten JC, Stijnen T, Hofman A, Witteman JC, Breteler MM (2004) Inflammatory proteins in plasma and the risk of dementia: the Rotterdam Study. Arch Neurol 61:668-72 CrossRef
19. Euser SM, Sattar N, Witteman JC, Bollen EL, Sijbrands EJ, Hofman A, Perry IJ, Breteler MM, Westendorp RG (2010) A prospective analysis of elevated fasting glucose levels and cognitive function in older people: results from PROSPER and the Rotterdam Study. Diabetes 59:1601-607 CrossRef
20. Feinkohl I, Keller M, Robertson CM, Morling JR, Williamson RM, Nee LD, McLachlan S, Sattar N, Welsh P, Reynolds RM, Russ TC, Deary IJ, Strachan MW, Price JF, On behalf of the Edinburgh Type 2 Diabetes Study I (2013) Clinical and subclinical macrovascular disease as predictors of cognitive decline in older patients with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care 36(9):2779-786 CrossRef
21. Fischer AL, de Frias CM, Yeung SE, Dixon RA (2009) Short-term longitudinal trends in cognitive performance in older adults with type 2 diabetes. J Clin Exp Neuropsychol 31:809-22 CrossRef
22. Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-98 CrossRef
23. Fuchs T, Trollor JN, Crawford J, Brown DA, Baune BT, Samaras K, Campbell L, Breit SN, Brodaty H, Sachdev P, Smith E (2013) Macrophage inhibitory cytokine-1 is associated with cognitive impairment and predicts cognitive decline—the Sydney Memory and Aging Study. Aging cell 12(5):882-89 CrossRef
24. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT (2008) Effects of intensive glucose lowering in type 2 diabetes. New England J Med 358:2545-559 CrossRef
25. Gregg EW, Yaffe K, Cauley JA, Rolka DB, Blackwell TL, Narayan KM, Cummings SR (2000) Is diabetes associated with cognitive impairment and cognitive decline among older women? Study of Osteoporotic Fractures Research Group. Arch Intern Med 160:174-80 CrossRef
26. Grodstein F, Chen J, Wilson RS, Manson JE (2001) Type 2 diabetes and cognitive function in community-dwelling elderly women. Diabetes Care 24:1060-065 CrossRef
27. Hassing LB, Grant MD, Hofer SM, Pedersen NL, Nilsson SE, Berg S, McClearn G, Johansson B (2004) Type 2 diabetes mellitus contributes to cognitive decline in old age: a longitudinal population-based study. J Int Neuropsychol Soc 10:599-07 CrossRef
28. Ho N, Sommers MS, Lucki I (2013) Effects of diabetes on hippocampal neurogenesis: links to cognition and depression. Neurosci Biobehav Rev 37:1346-362 CrossRef
29. Kaplan E (2001) The Boston naming test. Lippincott Williams & Wilkins, Philadelphia
30. Karim S, Hopkins S, Purandare N, Crowther J, Morris J, Tyrrell P, Burns A (2013) Peripheral inflammatory markers in amnestic mild cognitive impairment. Int J Geriatr Psychiatry. doi:10.1002/gps.3988
31. Kochan NA, Slavin MJ, Brodaty H, Crawford JD, Trollor JN, Draper B, Sachdev PS (2010) Effect of different impairment criteria on prevalence of ‘objective-mild cognitive impairment in a community sample. Am J Geriatr Psychiatry 18:711-22 CrossRef
32. Kooistra M, Geerlings MI, Mali WP, Vincken KL, van der Graaf Y, Biessels GJ, on behalf of the S-MRSG (2013) Diabetes mellitus and progression of vascular brain lesions and brain atrophy in patients with symptomatic atherosclerotic disease. The SMART-MR study. J Neurol Sci 332(1-):69-4 CrossRef
33. Launer LJ, Miller ME, Williamson JD, Lazar RM, Gerstein HC, Murray AM, Sullivan M, Horowitz KR, Ding J, Marcovina S, Lovato LC, Lovato J, Margolis KL, O’Connor P, Lipkin EW, Hirsch J, Coker L, Maldjian J, Sunshine JL, Truwit C, Davatzikos C, Bryan RN (2011) Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurol 10:969-77 CrossRef
34. Liu T, Wen W, Zhu W, Kochan NA, Trollor JN, Reppermund S, Jin JS, Luo S, Brodaty H, Sachdev PS (2011) The relationship between cortical sulcal variability and cognitive performance in the elderly. NeuroImage 56:865-73 CrossRef
35. Manschot SM, Brands AM, van der Grond J, Kessels RP, Algra A, Kappelle LJ, Biessels GJ (2006) Brain magnetic resonance imaging correlates of impaired cognition in patients with type 2 diabetes. Diabetes 55:1106-113 CrossRef
36. Manschot SM, Biessels GJ, de Valk H, Algra A, Rutten GE, van der Grond J, Kappelle LJ (2007) Metabolic and vascular determinants of impaired cognitive performance and abnormalities on brain magnetic resonance imaging in patients with type 2 diabetes. Diabetologia 50:2388-397 CrossRef
37. Marioni RE, Strachan MW, Reynolds RM, Lowe GD, Mitchell RJ, Fowkes FG, Frier BM, Lee AJ, Butcher I, Rumley A, Murray GD, Deary IJ, Price JF (2010) Association between raised inflammatory markers and cognitive decline in elderly people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes 59:710-13 CrossRef
38. Okereke OI, Kang JH, Cook NR, Gaziano JM, Manson JE, Buring JE, Grodstein F (2008) Type 2 diabetes mellitus and cognitive decline in two large cohorts of community-dwelling older adults. J Am Geriatr Soc 56:1028-036 CrossRef
39. Reitan RM, Wolfson D (1985) The Halstead-Reitan neuropsycholgical test battery: theory and clinical interpretation. Neuropsychological Press, Tucson
40. Rey A (1964) L’examen clinique en psychologie. Presses Universitaires de France, Paris, 1964
41. Reynolds RM, Strachan MW, Labad J, Lee AJ, Frier BM, Fowkes FG, Mitchell R, Seckl JR, Deary IJ, Walker BR, Price JF (2010) Morning cortisol levels and cognitive abilities in people with type 2 diabetes: the Edinburgh type 2 diabetes study. Diabetes Care 33:714-20 CrossRef
42. Sachdev PS, Brodaty H, Reppermund S, Kochan NA, Trollor JN, Draper B, Slavin MJ, Crawford J, Kang K, Broe GA, Mather KA, Lux O (2010) The Sydney Memory and Ageing Study (MAS): methodology and baseline medical and neuropsychiatric characteristics of an elderly epidemiological non-demented cohort of Australians aged 70-0 years. Int Psychogeriatr 22:1248-264 CrossRef
43. Samaras K, Crawford J, Baune BT, Campbell LV, Smith E, Lux O, Brodaty H, Trollor JN, Sachdev P (2012) The value of the metabolic syndrome concept in the elderly: is it worth less than the sum of its parts? J Am Geriatr Soc 60:1734-741 CrossRef
44. Schmidt R, Launer LJ, Nilsson LG, Pajak A, Sans S, Berger K, Breteler MM, de Ridder M, Dufouil C, Fuhrer R, Giampaoli S, Hofman A (2004) Magnetic resonance imaging of the brain in diabetes: the Cardiovascular Determinants of Dementia (CASCADE) Study. Diabetes 53:687-92 CrossRef
45. Schuur M, Henneman P, van Swieten JC, Zillikens MC, de Koning I, Janssens AC, Witteman JC, Aulchenko YS, Frants RR, Oostra BA, van Dijk KW, van Duijn CM (2010) Insulin-resistance and metabolic syndrome are related to executive function in women in a large family-based study. Eur J Epidemiol 25:561-68 CrossRef
46. Seaquist ER, Miller ME, Fonseca V, Ismail-Beigi F, Launer LJ, Punthakee Z, Sood A (2013) Effect of thiazolidinediones and insulin on cognitive outcomes in ACCORD-MIND. J Diabetes Complicat 27(5):485-91 CrossRef
47. Spreen O, Benton AL (1969) Neurosensory Center Comprehensive Examination for Aphasia: manual of instructions (NCCEA). University of Victoria, Victoria
48. Strachan MW, Reynolds RM, Marioni RE, Price JF (2011) Cognitive function, dementia and type 2 diabetes mellitus in the elderly. Nat Rev Endocrinol 7:108-14 CrossRef
49. Tan ZS, Beiser AS, Fox CS, Au R, Himali JJ, Debette S, Decarli C, Vasan RS, Wolf PA, Seshadri S (2011) Association of metabolic dysregulation with volumetric brain magnetic resonance imaging and cognitive markers of subclinical brain aging in middle-aged adults: the Framingham Offspring Study. Diabetes Care 34:1766-770 CrossRef
50. Tiehuis AM, van der Graaf Y, Visseren FL, Vincken KL, Biessels GJ, Appelman AP, Kappelle LJ, Mali WP (2008) Diabetes increases atrophy and vascular lesions on brain MRI in patients with symptomatic arterial disease. Stroke 39:1600-603 CrossRef
51. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, Mazoyer B, Joliot M (2002) Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 15:273-89 CrossRef
52. van den Berg E, Reijmer YD, de Bresser J, Kessels RP, Kappelle LJ, Biessels GJ (2010) A 4 year follow-up study of cognitive functioning in patients with type 2 diabetes mellitus. Diabetologia 53:58-5 CrossRef
53. Wechsler D (1981) Wechsler adult intelligence scale—revised: manual. Psychological Corporation, New York
54. Wechsler D (1997a) Wechsler Adult Intelligence Scale—version III (WAIS-III). Psychological Corporation, Harcourt Brace & Co, San Antonio
55. Wechsler D (1997b) Wechsler Memory Scale—version III (WMS-III). Psychological Corporation, Harcourt Brace & Co, San Antonio
56. Yaffe K, Blackwell T, Kanaya AM, Davidowitz N, Barrett-Connor E, Krueger K (2004) Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology 63:658-63 CrossRef
57. Yaffe K, Haan M, Blackwell T, Cherkasova E, Whitmer RA, West N (2007) Metabolic syndrome and cognitive decline in elderly Latinos: findings from the Sacramento Area Latino Study of Aging study. J Am Geriatr Soc 55:758-62 CrossRef
58. Yaffe K, Falvey CNH, Schwartz AV, Simonsick EM, Satterfield S, Cauley JA, Rosano C, Launer LJ, Strotomeyer ES, Harris TB (2012) Diabetes, glucose control, and 9-year cognitive decline among older adults without dementia. Arch Neurol 69(9):1170-175. doi:10.10001/archneurol.2012.1117 CrossRef
59. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, Leirer VO (1982) Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 17:37-9 CrossRef
60. Zhang CE, Tian Q, Wei W, Peng JH, Liu GP, Zhou XW, Wang Q, Wang DW, Wang JZ (2008) Homocysteine induces tau phosphorylation by inactivating protein phosphatase 2A in rat hippocampus. Neurobiol Aging 29:1654-665 CrossRef
61. Zhang H, Sachdev PS, Wen W, Kochan NA, Crawford JD, Brodaty H, Slavin MJ, Reppermund S, Draper B, Zhu W, Kang K, Trollor JN (2012) Gray matter atrophy patterns of mild cognitive impairment subtypes. J Neurol Sci 315:26-2 CrossRef - 作者单位：Katherine Samaras (1) (2)
Helen L. Lutgers (1)
Nicole A. Kochan (3) (7)
John D. Crawford (3)
Lesley V. Campbell (1) (2)
Wei Wen (3) (7)
Melissa J. Slavin (3) (5)
Bernard T. Baune (4)
Darren M. Lipnicki (3)
Henry Brodaty (3) (5)
Julian N. Trollor (3) (6)
Perminder S. Sachdev (3) (7)
1. Diabetes and Obesity Program, Garvan Institute of Medical Research, 384 Victoria St, Darlinghurst, NSW, 2010, Australia
2. Department of Endocrinology, St Vincent’s Hospital, Darlinghurst, NSW, Australia
3. Centre for Healthy Brain Ageing, School of Psychiatry, University of New South Wales, Randwick, NSW, Australia
7. Neuropsychiatric Institute, Prince of Wales Hospital, Randwick, NSW, Australia
5. Dementia Collaborative Research Centre Assessment and Better Care, School of Psychiatry, University of New South Wales, Kensington, Australia
4. Department of Psychiatry, University of Adelaide, Adelaide, SA, Australia
6. Department of Developmental Disability Neuropsychiatry, School of Psychiatry, Faculty of Medicine, University of New South Wales, Kensington, Australia - ISSN：1574-4647
文摘
Type 2 diabetes predicts accelerated cognitive decline and brain atrophy. We hypothesized that impaired fasting glucose (IFG) and incident glucose disorders have detrimental effects on global cognition and brain volume. We further hypothesized that metabolic and inflammatory derangements accompanying hyperglycaemia contribute to change in brain structure and function. This was a longitudinal study of a community-dwelling elderly cohort with neuropsychological testing (n--80) and brain volumes by magnetic resonance imaging (n--12) measured at baseline and 2 years. Primary outcomes were global cognition and total brain volume. Secondary outcomes were cognitive domains (processing speed, memory, language, visuospatial and executive function) and brain volumes (hippocampal, parahippocampal, precuneus and frontal lobe). Participants were categorised as normal, impaired fasting glucose at both assessments (stable IFG), baseline diabetes or incident glucose disorders (incident diabetes or IFG at 2 years). Measures included inflammatory cytokines and oxidative metabolites. Covariates were age, sex, education, non-English speaking background, smoking, blood pressure, lipid-lowering or antihypertensive medications, mood score, apolipoprotein E genotype and baseline cognition or brain volume. Participants with incident glucose disorders had greater decline in global cognition and visuospatial function compared to normal, similar to that observed in baseline diabetes. Homocysteine was independently associated with the observed effect of diabetes on executive function. Apolipoprotein E genotype did not influence the observed effects of diabetes on cognition. Incident glucose disorders and diabetes were also associated with greater 2-year decline in total brain volume, compared to normal (40.0?±-.2 vs. 46.7?±-.7?mm3 vs. 18.1?±-.2, respectively, p-lt;-.005). Stable IFG did not show greater decline in global cognition or brain volumes compared to normal. Incident glucose disorders, like diabetes, are associated with accelerated decline in global cognition and brain volumes in non-demented elderly, whereas stable IFG is not. Preventing deterioration in glucose metabolism in the elderly may help preserve brain structure and function.